A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical trial NCT04177823 · COMPLETED
Trial details
- NCT number
- NCT04177823
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-09
- Primary completion
- 2021-12-30
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.